Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial.
| Author | |
|---|---|
| Abstract |
:
In the LATITUDE trial, addition of abiraterone acetate plus prednisone to androgen deprivation therapy (ADT) improved overall survival compared with placebos plus ADT in patients with newly diagnosed, high-risk, metastatic castration-naive prostate cancer. Understanding the effects of treatments on patient-reported outcomes (PROs) and health-related quality of life (HRQOL) is important for treatment decisions; therefore we aimed to analyse the effects of ADT plus abiraterone acetate and prednisone versus ADT plus placebos on PROs and HRQOL in patients in the LATITUDE study. |
| Year of Publication |
:
2018
|
| Journal |
:
The Lancet. Oncology
|
| Date Published |
:
2018
|
| ISSN Number |
:
1470-2045
|
| DOI |
:
10.1016/S1470-2045(17)30911-7
|
| Short Title |
:
Lancet Oncol
|
| Download citation |
